Call AI in biotech hype at your peril. There are real reasons that pharmaceutical companies are embracing this technology ...

The real drug development delay? Bad communication.

Osanni launched three years ago with a $27 million series A and has kept purposefully quiet ever since, founder and CEO ...

Fierce Biotech Week brings together the industry’s top innovators, decision-makers, and visionaries driving the future of drug development, clinical research, business development and licensing, TMF, ...

The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with ...

Chugai Pharmaceutical, which is 60% owned by Roche, is planting its flag in South San Francisco as it scouts for fresh Bay ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Gavin Newsom turns on the press for asking Trump softball questions in the Oval Office - The California governor described ...

KBI CSO Sigma Mostafa speaks with BioProcess International's Chris Spivey about the company's 30 years of partnering with ...

Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

DES MOINES, Iowa — In an exclusive interview with WHO 13 News, Congressman Zach Nunn introduced legislation in Washington, ...